ClinicalTrials.gg
RecruitingNCT07647107Updated Nov 12, 2026

A Phase I Study of Lipovaxin Tuberculosis Vaccine in Adult Healthy Populations

A Phase 1 interventional study of LipovaxinS4-EAH (Middle Dose) and LipovaksinS4-EAH (High Dose) in Tuberculosis and TB Infection, sponsored by PT Bio Farma. Recruiting at 1 site in Indonesia. Open to participants aged 18 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by PT Bio Farma · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Sep 2026; still recruiting 2 months later.
Updated Nov 12, 2026Now RecruitingSite recruiting status changed+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 40 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 37 studies in Tuberculosis with a site in Indonesia — 8 open to participants now, 13 under way, 3 of them phase 3. Tuberculosis · Indonesia.

Planned enrollment
19th of 34
60 · median 92
Started
2026
with 3 others
Phase 1
3 of 37
1 open now
Primary completion
2027-07
later than 9 of 12 live
Registered
34th of 37
by date

Among the 37 studies in Tuberculosis with a site in Indonesia, this one is the 19th largest by planned enrollment of the 34 interventional ones that give a count, is one of 4 that started in 2026, is one of 3 in phase 1, reaches primary completion later than 9 of the 12 other live ones, and was the 34th registered.

Tuberculosis

1,171 studies on the registry are indexed under Tuberculosis; 176 are open to participants now.

Browse Tuberculosis studies →

Open to participants now

8 of the 37 studies in Tuberculosis with a site in Indonesia are open now. Recruiting first, the newest first:

2 more — sign in →

All 8 open studies →

A study can be open while its sites in Indonesia have not opened yet or have stopped. Only those recruiting at a site in Indonesia →

Who these studies take

Of the 112 Tuberculosis studies recruiting now, 65 (58%) set no upper age limit and 37 (33%) stop at 75 or younger; 49 take children under 18; 31 take healthy volunteers.

This study: 18 Years to 40 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 37 studies in Tuberculosis with a site in Indonesia, or all of them as a file.
02

Study summary

A Phase I, Double-Blind, Randomized, Placebo Controlled Trial to Evaluate Safety and Immunogenicity of Lipovaxin Tuberculosis Vaccine (Bio Farma) in Healthy Populations Aged 18-40 Years in Indonesia

Read the detailed description

The primary objectives of this trial is to assess the safety of Lipovaxin in adults aged 18-40 years while the secondary objectives are; (1) To assess the frequency of antigen-specific CD4 and CD8 T cell responses measured by expression of IFN-y, IL-2, or TNF-α between groups, and 2.) To assess serum changes in the levels of antigen-specific total IgG antibodies

Participants will be given two dose of 0.5 ml of Lipovaxin or control IM deltoid region of upper arm. A total of 60 participants will be recruited and randomized to either receive Medium-dose/ High-dose Lipovaksin or Control.

The recruitment will start with 6 sentinel participants, randomised to received mid dose or control vaccine. After evaluation of safety for mid dose of Lipovaksin TB, recruitment will be continued to recruit 24 participants to receive either mid dose or control vaccine. Additionally, 6 sentinel participants will also be recruited to receive either high dose or control vaccine. After evaluation of safety of high dose Lipovaksin TB, recruitment will be continued to recruit the 24 participants to receive either high dose or control vaccine.

All subjects will be evaluated for the local and systemic reactions and safety assessments in 30 minutes, 7 days and 28 days after 1st and 2nd injection. Additionally, the participants will be evaluated on the cellular and humoral immunogenicity in D0 and 14 days after 2nd dose of vaccination.

03

Conditions studied

  • Tuberculosis
  • TB Infection

Browse trials for

Keywords

  • TB vaccine
  • Tuberculosis
  • Lipovaksin TB
04

Who can participate

Ages eligible
18 Years to 40 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Clinically Healthy participants aged 18-40 years;
  2. Participants have been informed properly regarding the study and signed the form.
  3. Participants will commit to comply with the instructions of the investigator and the schedule of the trial;
  4. Participants must have a negative IGRA and sputum.
  5. Clinically normal laboratory values for ureum, creatinine, , SGPT, complete blood count (CBC), urinalysis, coagulation test (PT, ), total cholesterol, Globulin/Albumin ratio and CRP

Exclusion criteria

Exclusion Criteria:

  1. Those who are currently diagnosed with tuberculosis or have a history of tuberculosis (positive IGRA or GenXpert sputum test or chest Xray suggestive of TB) and/or history of tuberculosis treatment; including TB Preventive Treatment (TPT);
  2. There are serious chronic diseases, or the disease is in the advanced stage that cannot be controlled smoothly, such as diabetes and thyroid disease;
  3. Currently suffering from or within 2 years of any of the following serious diseases, such as: advanced tumor, disease, progressive atherosclerosis, acute exacerbation of the , acute or progressive liver or kidney disease, congestive heart failure, etc.; based on interview with participants
  4. Those with known or suspected (or high-risk) immune function impairments or abnormalities, such as those receiving more than 20mg/day of systemic for 14 consecutive days within the last 4 weeks, within 3 months, and Those who received protein preparations or blood products or plasma extracts outside the gastrointestinal tract within 3 months;
  5. People with allergic constitution, such as those with a history of allergy to two or more drugs or foods; a history of severe allergy to any component of the test vaccine, such as: anaphylactic shock, allergic laryngeal edema, allergic purpura, thrombocytopenia Purpura, dyspnea, angioedema, etc.; or a history of the above-mentioned serious side effects after using any vaccine or drug in the past; history of bronchial asthma;
  6. Current patients with antibody positive for human immunodeficiency virus;
  7. Women who are pregnant, breastfeeding, or have a positive urine pregnancy test during the screening period, or before vaccination, or who have childbearing plans during the study period;
  8. Subjects receive any vaccination within 1 month before and after dosing;
  9. Those who have participated in any other clinical research and used the drug within 3 months before this clinical research;
  10. Any other situation that the researcher believes may affect the evaluation of the research.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
60 participants (estimated)

Study arms

  • Placebo comparator
    Control

    NacL 0.9%

    Biological: Placebo

  • Experimental
    Middle Dose

    Middle Dose (20 ug) LipovaxinS4-EAH

    Biological: LipovaxinS4-EAH (Middle Dose)

  • Experimental
    High Dose

    High Dose (25 ug) LipovaxinS4-EAH

    Biological: LipovaksinS4-EAH (High Dose)

Interventions

  • BiologicalLipovaxinS4-EAH (Middle Dose)

    0,5 mL of Middle Dose LipovaxinS4-EAH. Administered twice, 28 days apart

  • BiologicalLipovaksinS4-EAH (High Dose)

    0,5 mL of HIgh Dose LipovaxinS4-EAH. Administered twice, 28 days apart

  • BiologicalPlacebo

    0,5 mL of Placebo containing NaCl 0.9%. Administered twice, 28 days apart

06

What researchers measure

Primary outcomes

  1. Local and systemic reactions

    Local reactions and systemic events 30 minutes, 7 days and 28 days after 1st and 2nd dose of Vaccine/Placebo (additional 14 days after 1st dose for sentinel group)

    Time frame: 30 minutes, 7 days and 28 days after 1st injection and 2nd injection for all group, and 30 minutes, 7 days and 28 days after 1st injection and 2nd injection and 14 days after 1st dose for sentinel group

  2. Any AEs and SAEs

    Any Adverse Events (AEs) and Serious Adverse Events (SAEs)

    Time frame: until 6 months after 2nd injection

  3. Laboratory changes

    Laboratory changes in D0, 14 days after 1st dose (sentinel group) and 28 days after 2nd dose.

    Time frame: D0, 14 days after 1st injection (sentinel), 28 days after 2nd injection

Secondary outcomes

  1. Cellular Immunogenicity

    Intracellular cytokine staining of antigen specific T-cells (IFN-y, IL-2, or TNF-α) in D0 and 14 days after 2nd dose

    Time frame: D0 and 14 days after 2nd dose.

  2. Humoral Immunogenicity

    Geometric mean time (GMT), seropositive, seroconversion of total serum IgG antigen specific in D0 and 28 days after 2nd dose

    Time frame: D0 and 28 days after 2nd dose.

07

Study locations

1 of 1 sites recruiting
  • Cipto Mangunkusumo Hospital, Jl. Pangeran Diponegoro No. 71, Kenari, Jakarta Pusat, DKI Jakarta.
    Jakarta Pusat, DKI Jakarta 10430, Indonesia
    Recruiting
    • Sri R Hadinegoro · Contactlipovax.jkt@gmail.com · +62218314914
    • Sri R Hadinegoro · Principal investigator
    • Nina D Putri · Sub investigator
    • Robert Sinto · Sub investigator
    • Mira Yulianti · Sub investigator
    • Pratama Wicaksana · Sub investigator
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2026 (actual). Primary completion is estimated for Jul 2027, 10 months after the start.

Of 60 phase 1 interventional studies under Tuberculosis, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 25. This study's planned 10 months is close to that.

Start moved once since we started tracking on Sep 25, 2026: Aug 2026 → Sep 2026, on Nov 12, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 9, 2026
First posted
Jun 15, 2026
StartActual
Sep 8, 2026was Aug 2026
Primary completionEst.
Jul 2027
CompletionEst.
Aug 2027
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Nov 12, 2026
Sites
Cipto Mangunkusumo Hospital, Jl. Pangeran Diponegoro No. 71, Kenari, Jakarta Pusat, DKI Jakarta. is now Recruiting
Nov 12, 2026
Start date
Aug 2026→Sep 8, 2026 (actual)
Nov 12, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • Cipto Mangunkusumo Hospital, Jl. Pangeran Diponegoro No. 71, Kenari, Jakarta Pusat, DKI Jakarta. · Jakarta Pusat, IndonesiaContact added l•••@gmail.com · •••4914
Nov 12, 2026
Show all 1 update
  1. Nov 12, 2026
    Not yet recruiting→Recruiting
    Cipto Mangunkusumo Hospital, Jl. Pangeran Diponegoro No. 71, Kenari, Jakarta Pusat, DKI Jakarta. is now Recruiting
    Start date Aug 2026→Sep 8, 2026 (now actual)
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Cipto Mangunkusumo Hospital, Jl. Pangeran Diponegoro No. 71, Kenari, Jakarta Pusat, DKI Jakarta. · Jakarta Pusat, IndonesiaContact added l•••@gmail.com · •••4914
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07647107
Lead sponsor
PT Bio Farma
Collaborators
Fakultas Kedokteran Universitas Indonesia, Dr Cipto Mangunkusumo General Hospital
Responsible party
Sponsor
First posted
Jun 15, 2026
Start date
Sep 8, 2026
Primary completion
Jul 2027 (estimated)
Completion
Aug 2027 (estimated)
Last update
Nov 12, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion